Related Experiment Videos
[Angioedema associated with ACE inhibitors]
E W Nielsen1, P A Stenberg, E Einarsen
1Anestesiavdelingen, Nordland sentralsykehus, Bodø.
Summary
Angiotensin converting enzyme-inhibitor (ACE-inhibitor) angioedema, a potentially life-threatening swelling, may be underdiagnosed. Early intervention is crucial, and C1-inhibitor concentrate shows experimental promise for treatment.
Area of Science:
- Pharmacology and Toxicology
- Adverse Drug Reactions
- Immunology
Background:
- Angiotensin converting enzyme-inhibitors (ACE-inhibitors) are widely prescribed for cardiovascular conditions.
- Angioedema is a known, albeit infrequent, adverse effect of ACE-inhibitor therapy.
- Current incidence estimates for ACE-inhibitor-induced angioedema may underestimate its occurrence.
Observation:
- Swelling of the face, lips, tongue, and throat is often misattributed to other causes like food allergies.
- Angioedema attacks can manifest unpredictably, even after prolonged ACE-inhibitor use, complicating diagnosis.
- This non-immunogenic adverse effect results from local bradykinin accumulation due to inhibited breakdown by ACE.
Findings:
- Rapidly developing angioedema can lead to airway compromise and suffocation.
- Conventional treatments (steroids, antihistamines, epinephrine) are frequently ineffective.
- Laryngeal intubation can be challenging due to severe edema, necessitating prompt medical intervention.
Implications:
- The pathophysiology involves bradykinin pathway dysregulation, distinct from allergic reactions.
- Vulnerability factors predisposing individuals to ACE-inhibitor angioedema remain unidentified.
- C1-inhibitor concentrate is explored as a potential therapeutic agent for refractory ACE-inhibitor angioedema.